Cruzani (CZNI) Stock Price, News & Analysis

Company Overview

Cruzani, Inc., trading under the symbol CZNI on the OTC Markets, is a clinical-stage biotechnology company specializing in the discovery and development of protein-based therapeutics. The firm’s proprietary platform employs high-throughput yeast surface display and combinatorial library techniques to identify small, complex proteins with enhanced stability and target specificity. By leveraging these technologies, Cruzani aims to accelerate the preclinical screening process and bring novel drug candidates to the clinic more efficiently.

The company’s pipeline encompasses both neurological and oncology programs, with lead candidates focused on modulating disease pathways implicated in neurodegenerative disorders such as Parkinson’s disease. Cruzani’s approach emphasizes engineered proteins that can cross biological barriers and maintain functional activity in target tissues, addressing key challenges in the delivery of biologic therapeutics. Early-stage data have demonstrated proof of concept for several novel protein scaffolds identified through the company’s platform.

Based in the United States, Cruzani collaborates with academic institutions and industry partners to advance its most promising candidates through preclinical and clinical development. The management team brings together expertise in protein engineering, drug discovery, and clinical operations. As a clinical-stage biotech, Cruzani continues to pursue strategic collaborations and financing to support the advancement of its programs toward regulatory milestones and potential commercialization.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 433.40 million shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Technology
• Industry: Software
• Sub-Industry: Application Software
• Current Symbol: OTCMKTS:CZNI
• CIK: 1381871
• Web: www.bowmo.com
• Phone: (646) 893-1112
• Fax: N/A
• Employees: 1
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A